Product Description: D609, an antitumoural xanthate, is a specific and competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor with a Ki of 6.4 μM. D609 is an antioxidative protector and has antiviral and anti-inflammatory activity[1][2][3].
Applications: Cancer-programmed cell death
Formula: C11H15KOS2
References: [1]E Amtmann, et al. The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res. 1996;22(6):287-94./[2]Lu Zhang, et al. D609 inhibits progression of preexisting atheroma and promotes lesion stability in apolipoprotein e-/- mice: a role of phosphatidylcholine-specific phospholipase in atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):411-8./[3]Gusain A, et al. Anti-proliferative effects of tricyclodecan-9-yl-xanthogenate (D609) involve ceramide and cell cycle inhibition.Mol Neurobiol. 2012 Jun;45(3):455-64. Epub 2012 Mar 14./[4]Rachele Pandolfi, et al. Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction. Thorax. 2017 May;72(5):460-471./[5]Kalluri HS, et al. D609 inhibits the proliferation of neural progenitor cells.Neuroreport. 2010 Jul 14;21(10):700-3.
CAS Number: 83373-60-8
Molecular Weight: 266.46
Compound Purity: 98.0
Research Area: Cancer; Infection; Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 2 mg/mL (ultrasonic)
Target: Phospholipase
English
Deutsch
